Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravitreal bevacizumab vs laser surgery for vision-threatening retinopathy of prematurity
2009-012609-20Phase 2Completed
- Sponsor
- Policlinico Gemelli
- Start
- May 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2 trial of bevacizumab in retinopathy of prematurity (ROP) (2 arms), sponsored by Policlinico Gemelli. Primary endpoints: Efficacy of bevacizumab on retinal neovascularization and Improvement of severe ROP prognosis. Started May 2009; status: completed.
02
Drugs
bevacizumab
03
Conditions
retinopathy of prematurity (ROP)
Beyond the preview
Go deeper on 2009-012609-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-012609-20.